White Paper: 10 Essential Considerations For Selecting The Optimal Clinical Trial Disclosure Solution

Recent and evolving laws, mandates and guidelines by regulatory bodies and international health organizations necessitate that drug, biologics and medical device companies disclose greater amounts of clinical trial information. The goal is to achieve more transparency through the disclosure on publicly-available databases of clinical trial results and adverse events.

As a range of new medicines and medical devices are being developed, the focus on transparency and public trust has only intensified. World health officials and national regulatory authorities anticipate that global registries of clinical trials for new prescription medicines and devices will go a long way to allay public fears about the clinical trials process.

In order to satisfy the demand for clinical trials disclosure, the industry is moving quickly to come up to speed on what precise steps need to be taken to comply with these requirements.